Lifeboat Foundation

A new neuroimaging study has found that individuals who consumed their first alcoholic drink before the age of 18 had weaker connections in the brain’s cognitive control network compared those who consumed their first alcoholic drink after the age of 18. This suggests that starting to drink alcohol at a young age might make this brain network less effective. The study was published in Psychiatry Research: Neuroimaging.

Although the adverse effects of alcohol consumption and related long-term health risks are well known, it is estimated that 30% of youth in the United States use alcohol by the eighth grade. 62% of adolescents report drinking their first alcoholic drink by the time they graduate from high school, around 18 years of age.

Studies have found that individuals who start using alcohol earlier are more likely to develop alcohol-related problems later in life. Individuals who drink their first alcoholic drink earlier are also more likely to get drunk for the first time at an earlier age. They are also more likely to participate in binge drinking i.e., to consume more than 5 standard drinks for men or more than 4 for women on a single occasion.

In a new study funded by a $3 million grant from the National Institutes of Health (NIH), University of Missouri researcher Kiho Lee, an associate professor in the College of Agriculture, Food and Natural Resources, will use gene editing to investigate the building blocks of disease.

Viral hepatitis is an inflammatory liver disease caused by infection with any of the known hepatitis viruses—A, B, C, D, and E. Most of the global viral hepatitis burden is from hepatitis B and C, which affect 354 million people and result in 1.1 million deaths annually. The Centers for Disease Control and Prevention estimates that in 2020 there were 14,000 and 50,300 new acute infections of hepatitis B and C in the United States, respectively, while at least 880,000 people in the country were living with chronic (long-term) hepatitis B and 2.4 million people had chronic hepatitis C. About half of those with viral hepatitis are unaware of their infection. Chronic and persistent inflammation from the disease can lead to liver failure, cirrhosis, or liver cancer. Viral hepatitis affects all ages and there are pronounced inequities in disease outcomes in the United States. Hepatitis B and C disproportionately affect people living with HIV, and HIV increases the rate of complications and death in people with viral hepatitis.

On this World Hepatitis Day, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, shares a snapshot of its investments in basic (laboratory), preclinical (laboratory/animal), and clinical (human) research to improve screening, prevention and treatment for hepatitis B and C. Scientists in the Hepatic Pathogenesis and Structural Virology sections of NIAID’s Laboratory of Infectious Diseases conduct basic and translational research to better understand hepatitis B and C disease progression, clarify the role of hepatitis viruses in liver cancer, and inform discovery of new vaccines, medicine and technologies. Both NIAID’s Division of AIDS (DAIDS) and the Division of Microbiology and Infectious Disease (DMID) support scientific programs focused on hepatitis B and C research and curative strategies, reflecting the widespread impact of viral hepatitis and the urgent need for safe and effective interventions.

Finding a hepatitis B cure.

The rising prevalence of antibiotic resistant microbial pathogens presents an ominous health and economic challenge to modern society. The discovery and large-scale development of antibiotic drugs in previous decades was transformational, providing cheap, effective treatment for what would previously have been a lethal infection. As microbial strains resistant to many or even all antibiotic drug treatments have evolved, there is an urgent need for new drugs or antimicrobial treatments to control these pathogens. The ability to sequence and mine the genomes of an increasing number of microbial strains from previously unexplored environments has the potential to identify new natural product antibiotic biosynthesis pathways. This coupled with the power of synthetic biology to generate new production chassis, biosensors and “weaponized” live cell therapeutics may provide new means to combat the rapidly evolving threat of drug resistant microbial pathogens. This review focuses on the application of synthetic biology to construct probiotic strains that have been endowed with functionalities allowing them to identify, compete with and in some cases kill microbial pathogens as well as stimulate host immunity. Weaponized probiotics may have the greatest potential for use against pathogens that infect the gastrointestinal tract: Vibrio cholerae, Staphylococcus aureus, Clostridium perfringens and Clostridioides difficile. The potential benefits of engineered probiotics are highlighted along with the challenges that must still be met before these intriguing and exciting new therapeutic tools can be widely deployed.

The discovery and application of antibiotic drugs is among the most significant accomplishments of medical science. Alexander Fleming’s discovery of penicillin (Fleming, 1929) and subsequent discovery and development of multiple classes of natural product antibiotics have been transformational to modern society. These compounds have yielded cheap and effective treatments for diseases caused by common bacterial infections that would previously have proven fatal. The advent of effective antibiotic drugs has made it possible to survive complex surgical procedures like open heart surgery and organ transplants and extended the average human life-span (Riley, 2005; Kaviani et al., 2020). The benefits of readily available antibiotic drugs have extended into agriculture and aquaculture, making it possible to increase productivity of farmed animals (Park et al., 1994; Patel et al., 2020).

Exercise gives your brain a “bubble bath of neurochemicals,” says Wendy Suzuki, a professor of neural science.

Up next, Forensic accountant explains why fraud thrives on Wall Street.
► https://youtu.be/GHKyDYtKGEg.

Continue reading “The #1 way to strengthen your mind is to use your body | Wendy Suzuki” »

Difficulty swallowing (dysphagia) affects your quality of life and your health. The ability to safely swallow is vital for adequate nutrition and hydration, and it prevents foods and liquids from entering your lungs, where they can cause pneumonia.

More often than not, studies of human biology are conducted when the body is under duress from infection or disease. Now, as part of a larger effort to delineate what “healthy” looks like, two Stanford Medicine teams have unfurled detailed molecular maps of healthy human intestinal and placental tissues. The maps, which capture cell types, cell quantity and other cellular nuances, are just two of a collection of maps that will establish a cellular baseline for the majority of the human body, including where cells in certain tissues congregate, how tissues develop during pregnancy and how cell-to-cell interactions drive human biology.

The studies, which published in Nature on July 19, are part of a larger effort spearheaded by the Human Biomolecular Atlas Program — called HuBMAP — funded by the National Institutes of Health. It aims to fill gaps in our knowledge of how the human body works when it’s in tip-top shape. Dozens of teams from the United States and Europe contribute to the HuBMAP consortium.

Continue reading “Stanford Medicine researchers take part in HuBMAP, showing what healthy human tissue looks like” »

Researchers have found that people with obstructive sleep apnea have an increased cardiovascular risk due to reduced blood oxygen levels, largely explained by interrupted breathing. Obstructive sleep apnea has long been associated with increased risk of cardiovascular issues, including heart attack, stroke, and death, but the findings from this study, published in the American Journal of Respiratory and Critical Care Medicine, show the mechanism mostly responsible for the link.

“These findings will help better characterize high-risk versions of obstructive sleep apnea,” said Ali Azarbarzin, Ph.D., a study author and director of the Sleep Apnea Health Outcomes Research Group at Brigham and Women’s Hospital and Harvard Medical School, Boston. “We think that including a higher-risk version of obstructive sleep apnea in a randomized clinical trial would hopefully show that treating sleep apnea could help prevent future cardiovascular outcomes.”

Researchers reviewed data from more than 4,500 middle-aged and older adults who participated in the Osteoporotic Fractures in Men Study (MrOS) and the Multi-Ethnic Study of Atherosclerosis (MESA), and sought to identify features of obstructive sleep apnea that could explain why some people were more likely than others to develop cardiovascular disease or related death.